

# Jean-Emmanuel Sarry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5604148/publications.pdf>

Version: 2024-02-01

87  
papers

4,834  
citations

117571

34  
h-index

98753

67  
g-index

98  
all docs

98  
docs citations

98  
times ranked

8142  
citing authors

#	ARTICLE	IF	CITATIONS
1	AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. <i>Cell Reports</i> , 2022, 38, 110197.	2.9	22
2	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1237-1252.	3.3	12
3	Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions. <i>Cell Death and Disease</i> , 2022, 13, 448.	2.7	22
4	Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-driven acute myeloid leukemia. <i>FEBS Open Bio</i> , 2021, 11, 48-60.	1.0	4
5	Reference Values for Hematology, Plasma Biochemistry, Bone Marrow Cytology and Bone Histology of NOD.Cg-Prkdc <sup>scid</sup> Il2rg <sup>tm1Wjl</sup> SzJ Immunodeficient Mice. <i>Journal of the American Association for Laboratory Animal Science</i> , 2021, 60, 4-17.	0.6	6
6	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	56
7	Disrupting Mitochondrial Electron Transfer Chain Complex I Decreases Immune Checkpoints in Murine and Human Acute Myeloid Leukemic Cells. <i>Cancers</i> , 2021, 13, 3499.	1.7	10
8	Autophagy is a major metabolic regulator involved in cancer therapy resistance. <i>Cell Reports</i> , 2021, 36, 109528.	2.9	55
9	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. <i>Nature Communications</i> , 2021, 12, 422.	5.8	36
10	Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy. <i>Leukemia</i> , 2021, 35, 417-432.	3.3	22
11	Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations. <i>Cancers</i> , 2021, 13, 5243.	1.7	6
12	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1204-1223.	5.7	42
13	SHED-Dependent Oncogenic Signaling of the PEAK3 Pseudo-Kinase. <i>Cancers</i> , 2021, 13, 6344.	1.7	6
14	Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2021, 13, 6353.	1.7	3
15	Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2933.	1.7	7
16	Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. <i>Nature Communications</i> , 2020, 11, 4056.	5.8	96
17	Microenvironmental Aspartate Preserves Leukemic Cells from Therapy-Induced Metabolic Collapse. <i>Cell Metabolism</i> , 2020, 32, 321-323.	7.2	3
18	Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation. <i>Haematologica</i> , 2020, 105, 987-9998.	1.7	18

#	ARTICLE	IF	CITATIONS
19	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 1725.	1.7	13
20	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1544-1565.	7.7	39
21	Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia. <i>Haematologica</i> , 2020, 105, e280-e284.	1.7	2
22	Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 5191-5203.	0.4	45
23	Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. <i>Oncogenesis</i> , 2019, 8, 39.	2.1	26
24	Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. <i>BMC Biology</i> , 2019, 17, 57.	1.7	31
25	Help from outside: cysteine to survive in AML. <i>Blood</i> , 2019, 134, 336-338.	0.6	5
26	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 131-142.	1.1	57
27	Combination of the MEK Inhibitor Trametinib and Pyvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models. <i>Blood</i> , 2019, 134, 2671-2671.	0.6	0
28	Targeting the SUMO Pathway Primes All-trans Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. <i>Cancer Research</i> , 2018, 78, 2601-2613.	0.4	45
29	Dexamethasone in hyperleukocytic acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 988-998.	1.7	49
30	Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. <i>Oncogene</i> , 2018, 37, 787-797.	2.6	82
31	RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 597-605.	3.3	22
32	Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3325.	1.8	46
33	Adrenomedullin Receptor Calcrl Drives Drug Resistance of Leukemic Stem Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1449-1449.	0.6	1
34	Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia. <i>Blood</i> , 2018, 132, 5238-5238.	0.6	2
35	Extracellular ATP and CD39 Regulates Mitochondrial Function and Cytarabine Resistance through Intrinsic PKA-ATF-PGC1 $\alpha$ Pathway in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2737-2737.	0.6	2
36	Assessment of tumor-infiltrating TCRV $\beta$ 3V $\beta$ 2 $\beta$ lymphocyte abundance by deconvolution of human cancers microarrays. <i>Oncolmmunology</i> , 2017, 6, e1284723.	2.1	134

#	ARTICLE	IF	CITATIONS
37	High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. <i>Leukemia</i> , 2017, 31, 2326-2335.	3.3	106
38	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. <i>Cancer Discovery</i> , 2017, 7, 716-735.	7.7	582
39	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. <i>Nature Communications</i> , 2017, 8, 1903.	5.8	84
40	Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment. <i>Cell Metabolism</i> , 2017, 26, 705-707.	7.2	140
41	Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 755-759.	3.3	20
42	Toward the Analysis of Mitochondria Isolated from Leukemic Cells with Electrochemically Instrumented Microwell Arrays. <i>Proceedings (mdpi)</i> , 2017, 1, .	0.2	2
43	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. <i>Blood</i> , 2016, 127, 882-892.	0.6	108
44	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. <i>Blood</i> , 2016, 128, 253-264.	0.6	320
45	CHK1 as a therapeutic target to bypass chemoresistance in AML. <i>Science Signaling</i> , 2016, 9, ra90.	1.6	73
46	Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53. <i>Molecular Cell</i> , 2016, 62, 890-902.	4.5	96
47	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 483-497.	4.2	68
48	Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach. , 2016, , .		0
49	Abstract A23: Characterization of novel molecular vulnerabilities provoking replicative and energetic stresses in pancreatic cancer cells. , 2016, , .		0
50	Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleukocytic Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1636-1636.	0.6	2
51	Antileukemic Activity of 2-Deoxy-D-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2364-2373.	1.9	52
52	A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e297-e297.	2.8	68
53	Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation. <i>Cancer &amp; Metabolism</i> , 2015, 3, 8.	2.4	36
54	The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations. <i>Blood</i> , 2015, 126, 2542-2542.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. PLoS ONE, 2015, 10, e0123721.	1.1	151
56	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.	0.8	20
57	Abstract 4068:In vivoanalysis of the residual disease uncovers early and late response of cytarabine-resistant cells in human acute myeloid leukemia. , 2015, , .		0
58	Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML. Blood, 2015, 126, 90-90.	0.6	0
59	In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells. Blood, 2015, 126, 4269-4269.	0.6	2
60	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. Cell Reports, 2014, 7, 1815-1823.	2.9	86
61	A Novel Path for ATRA Differentiation Therapy in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations. Blood, 2014, 124, 3727-3727.	0.6	1
62	Abstract 1336: Bortezomib induces the degradation of FLT3-ITD tyrosine kinase in acute myeloid leukemia through an autophagy-dependent mechanism. , 2014, , .		0
63	Abstract 2678: All-trans-retinoic acid as a new therapeutic approach to target isocitrate dehydrogenase mutations in acute myeloid leukemia. , 2014, , .		0
64	Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia. Blood, 2014, 124, 3767-3767.	0.6	0
65	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	0.6	53
66	Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia, 2013, 27, 2129-2138.	3.3	108
67	The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia, 2013, 27, 325-335.	3.3	17
68	Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. Blood, 2013, 122, 1651-1651.	0.6	2
69	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011, 96, 1792-1798.	1.7	164
70	Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion, 2011, 11, 342-350.	1.6	44
71	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R1 <sup>3c</sup> -deficient mice. Journal of Clinical Investigation, 2011, 121, 384-395.	3.9	336
72	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget, 2011, 2, 850-861.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Metabolic Capability to Induce the Pasteur Effect Mediates Sensitivity of Human Leukemic Cells to Metformin. <i>Blood</i> , 2011, 118, 2601-2601.	0.6	0
74	Ara-C Treatment of Acute Myeloid Leukemia Does Not Lead to Prolonged Enrichment of Stem Cells or a Cell Cycle Arrest. <i>Blood</i> , 2010, 116, 2178-2178.	0.6	0
75	Anti-Leukemic Activity of PIK-75, a PI3-Kinase p110 $\alpha$ Selective Inhibitor, In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 659-659.	0.6	0
76	A robust xenotransplantation model for acute myeloid leukemia. <i>Leukemia</i> , 2009, 23, 2109-2117.	3.3	113
77	Acute Myeloid Leukemia Stem Cells Cells Are Rare and Heterogeneous in Human Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 390-390.	0.6	3
78	Combined Mass Mapping and Biochemical Characterization of Grape $\beta$ -Glycosidase-enriched Extract. <i>Protein Journal</i> , 2008, 27, 258-266.	0.7	2
79	A Robust Xenotransplantation Model for Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2939-2939.	0.6	0
80	Analysis of the vacuolar luminal proteome of <i>Saccharomyces cerevisiae</i> . <i>FEBS Journal</i> , 2007, 274, 4287-4305.	2.2	33
81	Metabolomic, proteomic and biophysical analyses of <i>Arabidopsis thaliana</i> cells exposed to caesium stress. Influence of potassium supply. <i>Biochimie</i> , 2006, 88, 1533-1547.	1.3	79
82	The early responses of <i>Arabidopsis thaliana</i> cells to cadmium exposure explored by protein and metabolite profiling analyses. <i>Proteomics</i> , 2006, 6, 2180-2198.	1.3	348
83	Dynamics of <i>Arabidopsis thaliana</i> soluble proteome in response to different nutrient culture conditions. <i>Electrophoresis</i> , 2006, 27, 495-507.	1.3	24
84	Grape berry biochemistry revisited upon proteomic analysis of the mesocarp. <i>Proteomics</i> , 2004, 4, 201-215.	1.3	136
85	Plant and microbial glycoside hydrolases: Volatile release from glycosidic aroma precursors. <i>Food Chemistry</i> , 2004, 87, 509-521.	4.2	222
86	The protective function of the xanthophyll cycle in photosynthesis. <i>FEBS Letters</i> , 1994, 353, 147-150.	1.3	67
87	IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0